Literature DB >> 340155

Prophylaxis with isoniazid in inactive tuberculosis. A Veterans Administration Cooperative Study XII.

A Falk, G F Fuchs.   

Abstract

Based on a study indicating a significant rate of reactivation of tuberculosis in Veterans Administration patients with inactive disease, a cooperative study was initiated to determine the prophylactic effect of isoniazid on the rate of reactivation. A randomized double-blind study was designed, utilizing three regimens, two with isoniazid and one with placebo only. Two consecutive years of taking pills in one of the three regimens was followed by five years of observation. A total of 7,036 patients with inactive disease, some of whom had received prior chemotherapy, were entered into the study. Only 63 reactivations of tuberculosis were found, for a total rate of reactivation of 9/1,000 (less than 1%) over the seven-year period. Although no significant differences in the rate of reactivation were found among any of the regimens, there was a significant reduction in the rate of reactivation among those who had not received any prior chemotherapy and received isoniazid (INH) in this study, compared with those who received placebo only.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 340155     DOI: 10.1378/chest.73.1.44

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Screening indochinese refugee patients: result of 192 cases.

Authors:  N N Levinne; A P Choong
Journal:  Can Fam Physician       Date:  1980-10       Impact factor: 3.275

2.  Sensitivity of the quantiferon-gold in-tube assay in sputum smear positive TB cases in Indonesia.

Authors:  Merrin Rutherford; Bachti Alisjahbana; Winni Maharani; Hedy Sampurno; Reinout van Crevel; Philip C Hill
Journal:  PLoS One       Date:  2010-08-09       Impact factor: 3.240

3.  Miliary tuberculosis occurred after immunosuppressive drug in PNH patient with completely cured tuberculosis; a case report.

Authors:  Jihyun Lee; Soojung Gong; Byounghoon Lee; Soyoung Lee; Jungae Lee; Naeyu Kim
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-05-03       Impact factor: 3.944

4.  Factors Associated With Latent Tuberculosis Infection Treatment Failure Among Patients With Commercial Health Insurance-United States, 2005-2016.

Authors:  Shareen A Iqbal; Cheryl J Isenhour; Gerald Mazurek; Adam J Langer; Man-Huei Chang; Benedict I Truman
Journal:  J Public Health Manag Pract       Date:  2021 Jul-Aug 01

5.  Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.

Authors:  Timothy R Sterling; Gibril Njie; Dominik Zenner; David L Cohn; Randall Reves; Amina Ahmed; Dick Menzies; C Robert Horsburgh; Charles M Crane; Marcos Burgos; Philip LoBue; Carla A Winston; Robert Belknap
Journal:  MMWR Recomm Rep       Date:  2020-02-14

Review 6.  Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy.

Authors:  Hyung Woo Kim; Ju Sang Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2018-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.